Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)
1481 results found
2024 ∙ Yeh, Y. T. Tsai, T. F.
Drug- or Vaccine-Induced/Aggravated Psoriatic Arthritis: A Systematic Review
Adults Older adults COVID-19 Tuberculosis Safety
Rating:
Critically low
2024 ∙ Skare, T. L. de Carvalho, J. F. de Medeiros, I. R. T. Shoenfeld, Y.
Ear abnormalities in chronic fatigue syndrome (CFS), fibromyalgia (FM), Coronavirus-19 infectious disease (COVID) and long-COVID syndrome (PCS), sick-building syndrome (SBS), post-orthostatic tachycardia syndrome (PoTS), and autoimmune/inflammatory syndrome induced by adjuvants (ASIA): A systematic review
All age groups COVID-19 Safety
Rating:
Critically low
2024 ∙ Burch, E. Khan, S. A. Stone, J. Asgharzadeh, A. Dawe, J. Ward, Z. Brooks-Pollock, E. Christensen, H.
Early mathematical models of COVID-19 vaccination in high-income countries: a systematic review
All age groups COVID-19 Modeling
Rating:
Not applicable
2024 ∙ Chang, E. Li, H. Zheng, W. Zhou, L. Jia, Y. Gu, W. Cao, Y. Zhu, X. Xu, J. Liu, B. You, M. Liu, K. Wang, M. Huang, W.
Economic Evaluation of COVID-19 Immunization Strategies: A Systematic Review and Narrative Synthesis
All age groups COVID-19 Economic aspects
Rating:
Not applicable
2024 ∙ Zeinab, D. Shahin, N. Fateme, M. Saeed, B. F.
Economic evaluation of vaccination against COVID-19: A systematic review
All age groups COVID-19 Economic aspects
Rating:
Not applicable
2024 ∙ Goryaynov, S. Gurova, O.
Effect of Platform Type on Clinical Efficacy of SARS-CoV-2 Vaccines in Prime Vaccination Settings: A Systematic Review and Meta-Regression of Randomized Controlled Trials
All age groups COVID-19 Efficacy/effectiveness
Rating:
Critically low
2024 ∙ Fernández-García, S. Del Campo-Albendea, L. Sambamoorthi, D. Sheikh, J. Lau, K. Osei-Lah, N. Ramkumar, A. Naidu, H. Stoney, N. Sundaram, P. Sengupta, P. Mehta, S. Attarde, S. Maddock, S. Manning, M. Meherally, Z. Ansari, K. Lawson, H. Yap, M. Kew, T. Punnoose, A. Knight, C. Sadeqa, E. Cherian, J. Ravi, S. Chen, W. Walker, K. O'Donoghue, K. van Wely, M. van Leeuwen, E. Kostova, E. Kunst, H. Khalil, A. Brizuela, V. Kara, E. Kim, C. R. Thorson, A. Oladapo, O. T. Mofenson, L. Gottlieb, S. L. Bonet, M. Moss, N. Zamora, J. Allotey, J. Thangaratinam, S. Preg, C. O. V. Living Systematic Review Consortium
Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis
Pregnant women COVID-19 Efficacy/effectiveness Safety
Rating:
Critically low
2024 ∙ Li, K. Xia, Y. Ye, H. Sun, X. Shi, B. Wu, J.
Effectiveness and safety of immune response to SARS‑CoV‑2 vaccine in patients with chronic kidney disease and dialysis: A systematic review and meta‑analysis
All age groups COVID-19 Efficacy/effectiveness Safety
Rating:
Critically low
2024 ∙ Dang, W. Long, I. Zhao, Y. Xiang, Y. T. Smith, R. D.
Effectiveness of COVID-19 Vaccines in People with Severe Mental Illness: A Systematic Review and Meta-Analysis
All age groups COVID-19 Efficacy/effectiveness
Rating:
Critically low
2024 ∙ Pardo, I. Maezato, A. M. Callado, G. Y. Gutfreund, M. C. Hsieh, M. K. Lin, V. Kobayashi, T. Salinas, J. L. Subramanian, A. Edmond, M. B. Diekema, D. J. Rizzo, L. V. Marra, A. R.
Effectiveness of heterologous and homologous COVID-19 vaccination among immunocompromised individuals: a systematic literature review and meta-analysis
All age groups COVID-19 Efficacy/effectiveness Administration
Rating:
Critically low
Loading...